GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:16 2024-06-06 am EDT 5-day change 1st Jan Change
1,640 GBX -0.64% Intraday chart for GSK plc -6.10% +13.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK Closes Up to $50 Million Purchase of US-based Elsie Biotechnologies MT
GSK: acquisition of US biotech Elsie CF
GSK Buys Elsie Biotechnologies for Up to $50 Million DJ
GSK Buys Elsie Biotechnologies for $50 Million MT
GSK plc acquired Elsie Biotechnologies for $50 million. CI
HSBC Lifts GSK PT, Maintains Reduce Rating MT
Berenberg raises Taylor Wimpey to 'buy' AN
GSK : DZ Bank remains Neutral ZD
Just when you think you've got it all figured out... Our Logo
GSK PLC : Frightened markets create an entry opportunity in GSK Alphavalue
GSK : Receives a Buy rating from UBS ZD
GSK : Receives a Buy rating from Deutsche Bank ZD
GSK: positive results in rectal cancer CF
ANALYST RECOMMENDATIONS : Kinder Morgan, Marathon Petroleum, Autodesk, Cloudflare, Okta... Our Logo
GSK : Buy rating from Jefferies ZD
Top Midday Stories: NYSE Resolves Technical Issues; Paramount, Skydance Agree to Merger Terms; Waste Management to Acquire Stericycle; GameStop Soars on 'Roaring Kitty' Stake Purchase MT
GSK's Zantac Woes Weigh on FTSE 100 MT
FTSE 100 down amid shaky start in New York AN
Global markets live: GSK, Walt Disney, Blackstone, Boeing, Microsoft... Our Logo
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading MT
GSK’s Rectal Cancer Drug Shows 100% Complete Response Rate in Longer-term Phase 2 Trial MT
Trending : GSK Shares Tumble on Zantac's Legal Setback DJ
Sector Update: Health Care Stocks Steady Premarket Monday MT
GSK Says Cancer Drug Jemperli Shows 100% Clinical Response Rate in Long-Term Data From Mid-Stage Trial MT
GSK immunotherapy bowel cancer drug works for 100% of patients AN
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.4 GBP
Average target price
20.36 GBP
Spread / Average Target
+24.17%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. Abu Dhabi to Host GSK's Regional Vaccine Hub Under New Health Partnership